Argos Therapeutics (ARGS) Tops Q3 EPS by 3c

Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights

- Dr. Richard D. Katz Joined as Chief Financial Officer -

- Raised Gross Proceeds of $50 million in Follow-on Offering -

- First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in HIV -

- Investor Day Scheduled for December 7, 2016 -

- Third Quarter Results Conference Call and Webcast Today, November 14th, at 8:30 a.m. ET -

DURHAM, N.C., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS), an immuno-oncology company focused on the... More

Argos Therapeutics to Participate in Upcoming Investor Conferences

DURHAM, N.C., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq: ARGS) (Argos), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be participating in the Stifel 2016 Healthcare Conference and the ROTH Innovations in Oncology Corporate Access Day.

The Stifel 2016 Healthcare Conference will take place November 15-16 at the Lotte New York Palace in New York City. Argos management will be presenting on Wednesday, November 16th from 2:15-2:55pm ET in the Holmes... More

Argos Therapeutics to Participate in SITC 2016 Annual Meeting

DURHAM, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq: ARGS) (Argos), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be presenting at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting to be held November 11-13 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

Mark DeBenedette, Ph.D., director of immunology for Argos, will present two posters on Friday, November 11th from 12:15-1:30pm ET in Prince... More